Navigation Links
Cambrex Reports Fourth Quarter and Full Year 2009 Results
Date:2/10/2010

n two large capital projects for which the majority of work has since been completed.  

Steven M. Klosk, President and Chief Executive Officer, said, "We are pleased to finish 2009 at the high end of our prior earnings guidance, with just over $47 million in EBITDA.  We successfully managed working capital and expense levels throughout the business and reduced net debt by nearly $23 million during the year.

"As we entered 2009 the macro-economy suggested a conservative approach that led us to focus on reducing costs and maximizing cash flow.  While the outlook for the economy appears to have stabilized as we start 2010, our smaller customers continue to face a difficult funding environment and pricing pressures continue to exist in most product categories.  The 2010 forecasts for certain of our larger products are lower than we expected, and in some cases lower than 2009, for a variety of reasons.  We renegotiated an extension of an important contract for certain drug delivery products during the fourth quarter, and made price and volume concessions in order to maintain the majority of the share of this business over the next three years.  These are key factors contributing to our guidance of flat to lower sales and profits for 2010.

"We have opportunities to grow revenues through the advancement of projects in our pipeline of late stage development products, within our controlled substances and drug delivery categories and through the launch of new generic APIs.  However, we are convinced that we need to invest more aggressively, both internally and externally, in niche markets, novel technologies, and new geographies that generate sustainable growth.  Of course, we will continue to identify ways to further reduce costs and increase cash flow as we focus on growing the business."

'/>"/>

SOURCE Cambrex Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. Cambrex Presentation at the JPMorgan Healthcare Conference to be Webcast
2. Cambrex to Announce Fourth Quarter and Full Year 2007 Financial Results on February 14, 2008
3. Cambrex Appoints Steven M. Klosk as President and CEO
4. Cambrex Reports Third Quarter 2008 Results
5. Cambrex Receives Notice Regarding NYSE Listing
6. Cambrex Reports First Quarter 2009 Results
7. Cambrex Continuous-Flow Microwave-Assisted Organic Synthesis Technology Nominated for 2009 Innovations Award
8. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
9. QMed, Inc. Reports July Medicare SNP Enrollments
10. Phlo Affiliate Reports Expanded Coverage to Oregon Border
11. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2015)... , Sept. 3, 2015  Guardant Health®, the ... abstracts highlighting the performance and clinical utility of ... for oral and poster presentations at the International ... World Conference on Lung Cancer. These abstracts were ... of California, Davis; the University of Chicago; Sarah ...
(Date:9/3/2015)... ... September 03, 2015 , ... Park Systems ... on Sept. 17, 2015 at 9am PST. The webinar will focus on the methods ... known as 3D printing, additive manufacturing is a broad term that encompasses “addition or ...
(Date:9/2/2015)... , ... September 02, 2015 ... ... of regulatory compliance, quality systems, analytical testing, education and consulting services for ... expertise in medical device products/processes development, design control, validation, quality assurance and ...
(Date:9/2/2015)... 02, 2015 Research and ... Jain PharmaBiotech,s new report "Gene Therapy - Technologies, ... The markets for gene therapy are difficult to estimate ... and it is marketed in China ... the years 2014-2024. The estimates are based on epidemiology ...
Breaking Biology Technology:Leading Cancer Centers to Present Clinical Utility Data For Guardant360 At IASLC's 16th World Conference on Lung Cancer in Denver Sept. 6-9 2Leading Cancer Centers to Present Clinical Utility Data For Guardant360 At IASLC's 16th World Conference on Lung Cancer in Denver Sept. 6-9 3Leading Cancer Centers to Present Clinical Utility Data For Guardant360 At IASLC's 16th World Conference on Lung Cancer in Denver Sept. 6-9 4Park Systems Announces Webinar on 3D Printing and Additive Manufacturing for Nano-Scientists, Researchers in Nanotechnology and Engineers 2Park Systems Announces Webinar on 3D Printing and Additive Manufacturing for Nano-Scientists, Researchers in Nanotechnology and Engineers 3Park Systems Announces Webinar on 3D Printing and Additive Manufacturing for Nano-Scientists, Researchers in Nanotechnology and Engineers 4NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 2NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 3NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 4NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 5NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 6NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 7Global Gene Therapy Market Study 2015-2024 - Technologies, Markets and Companies Analysis 2
... The IN VIVO Blog , which provides news, insights and ... a Deal of the Year for 2008 -- ... than 2,500 reader votes were cast in this inaugural competition, ... the 13 nominees selected by The IN VIVO Blog,s writers ...
... ALTOS, Calif., Jan. 8 InteKrin Therapeutics, Inc.,will present ... at,9:00 a.m. Pacific Time on Tuesday, January 13, 2009, ... Francisco, California. InteKrin Therapeutics, President and,CEO Denny Lanfear will ... About InteKrin ( http://www.InteKrin.com ): , ...
... Jan. 8 AcelRx Pharmaceuticals, Inc.,announced today it ... Clinical,Development. In this new position, Dr. Skowronski ... protocols and providing medical input,and review of clinical ... Pamela,Palmer, the company,s Chief Medical Officer. , ...
Cached Biology Technology:The IN VIVO Blog Selects First Annual 'Deal of the Year' 2InteKrin Therapeutics to Present at the 27th Annual JP Morgan Healthcare Conference on Tuesday, January 13 2
(Date:8/31/2015)... BURNABY, Canada , August 31, 2015 ... use of biometrics technology in government digitization projects to drive ... According to a recently published TechSci Research report, " India ... India is projected to grow at ... in the market is anticipated on account of extensive use ...
(Date:8/24/2015)... , August 24, 2015 The consulting ... ,s largest biometrics manufacturer DERMALOG and its customized solutions and ... African Biometrics Company of the Year Award". DERMALOG is particularly ... .   -Cross reference: Picture is available ... - On Thursday evening, in South ...
(Date:8/19/2015)...  VOXX International Corporation (Nasdaq: VOXX ) ... Definitive Agreement to purchase the assets, inclusive of ... EyeLock through an acquiring entity.  Upon consummation of ... in the acquiring entity. The closing of the ...  Expanding on its existing supply chain and distribution ...
Breaking Biology News(10 mins):India Biometrics Market to Grow at Over 35% Through 2020, Says TechSci Research 2India Biometrics Market to Grow at Over 35% Through 2020, Says TechSci Research 3Frost & Sullivan Honors DERMALOG with Biometrics Prize for Achievements in Africa 2Frost & Sullivan Honors DERMALOG with Biometrics Prize for Achievements in Africa 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 2VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 4VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 5
... National Institute of Standards and Technology (NIST) and the ... evidence that engineered nanoparticles are able to accumulate within ... the team led by NIST chemist Bryant C. Nelson ... the capacity to enter plant root cells and generate ...
... senior researchers spanning seven faculties, the Renewable Energy Center ... multi-disciplinary and innovative hub in a crucial area of ... resources while advancing Israel,s economy and security. Now the ... an National Research Center for Petroleum Alternatives for Transportation ...
... (Edmonton) A medical researcher at the University of Alberta is working ... are genetic markers for autism. More than 15 scientists will examine ... see if the siblings are at high risk. , , ... intervention start before symptoms develop? , , If theres a ...
Cached Biology News:NIST/UMass study finds evidence nanoparticles may increase plant DNA damage 2Israel names Tel Aviv University's Renewable Energy Center a 'Center of Research Excellence' 2Israel names Tel Aviv University's Renewable Energy Center a 'Center of Research Excellence' 3Researchers across North America team up to find genetic markers for autism 2
... AgarACE Enzyme(a) is a unique agarose-digesting enzyme ... recovery of intact DNA or RNA from ... that low melting point (LMP) agarose melted ... equilibrated to the reaction temperature before hydrolysis. ...
Poly A Polymerase catalyzes the addition of AMP to the 3' hydroxyl terminus of RNA. Poly A Polymerase can add poly(C) and poly(U) to RNA but does so with much-reduced efficiency....
... high PCR specificity *High PCR specificity ... enzyme with unique QIAGEN PCR Buffer ... provided by the stringent built-in hot ... Master Mix and simple reaction setup ...
Recombinant Ovine IFN Tau. Active on sheep, cow, human and mouse cells. Activity: 5.7 x 10 7 u/mg...
Biology Products: